Details for New Drug Application (NDA): 205776
✉ Email this page to a colleague
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
Summary for 205776
Tradename: | RASUVO |
Applicant: | Medexus |
Ingredient: | methotrexate |
Patents: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 205776
Generic Entry Date for 205776*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 205776
Mechanism of Action | Folic Acid Metabolism Inhibitors |
Medical Subject Heading (MeSH) Categories for 205776
Suppliers and Packaging for NDA: 205776
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776 | NDA | Medexus Pharma Inc. | 59137-505 | 59137-505-01 | 1 PACKAGE in 1 CARTON (59137-505-01) / .15 mL in 1 PACKAGE (59137-505-00) |
RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776 | NDA | Medexus Pharma Inc. | 59137-505 | 59137-505-04 | 4 PACKAGE in 1 CARTON (59137-505-04) / .15 mL in 1 PACKAGE (59137-505-00) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 7.5MG/0.15ML (7.5MG/0.15ML) | ||||
Approval Date: | Jul 10, 2014 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jun 1, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | SUBCUTANEOUS INJECTION OF METHOTREXATE |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 10MG/0.20ML (10MG/0.20ML) | ||||
Approval Date: | Jul 10, 2014 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jun 1, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | SUBCUTANEOUS INJECTION OF METHOTREXATE |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 12.5MG/0.25ML (12.5MG/0.25ML) | ||||
Approval Date: | Jul 10, 2014 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Subscribe | Patent Expiration: | Jun 1, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | SUBCUTANEOUS INJECTION OF METHOTREXATE |
Complete Access Available with Subscription